Clinical trials: Cancer Disease Progression
Renal Cell Carcinoma, Progression
Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma.
PubMed, ScienceDirect, Cochrane Database of Systematic Reviews will be used to search for articles published from January 1965 to July 2019 using the key words "renal cancer", "lymphocyte to monocyte ratio" and "prognosis".
- Conditions
- Renal Cell Carcinoma, Progression, Lymphocyte Disorder, Monocytosis
- Trial name
- LMR (NCT04213664)
- Testing
- prognosis
- Where
- Spain
- Volunteers
- 4,666 people
- Sponsor
- Corporacion Parc Tauli
NeuroEndocrine Tumours
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Circulating tumour cells (CTCs) are detectable in the blood in around 50% of patients with functioning NeuroEndocrine Tumours (NET) arising in the midgut area (tumours which are secreting hormones and are located in the area in…
- Trial name
- CALM-NET (NCT02075606)
- Testing
- lanreotide acetate
- Where
- 14 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Ipsen
Adenocarcinoma
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work…
- Trial name
- NCT02213289
- Testing
- Trastuzumab, ABT-806, Bemarituzumab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Chicago
NSCLC (Non-small Cell Lung Cancer), Hyperprogression
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial
In metastatic NSCLC patients with PD-L1 expression ≥50%, a circulating immature (CD10-) LDNs level of ≥30.5% confers a high risk of hyperprogression (HPD) with first line single-agent immune-checkpoint inhibitors (SA-ICI).
- Trial name
- HYPERBOLIC (NCT07274384)
- Testing
- chemotherapy plus cemiplimab, Cemiplimab
- Volunteers
- 74 people
- Sponsor
- Università Vita-Salute San Raffaele
Cachexia, Cancer
Effectiveness of Nutritional Counselling and "Improved Atta" Supplementation in Cachexic Adult Indian Cancer Patients
Investigators are evaluating the nutritional role of IAtta supplementation along with nutritional counselling in delaying the progression of cachexia to refractory cachexia in adult cancer Indian patients.
- Trial name
- NCT02561143
- Testing
- Improved Atta, Wheat flour, Physical activity counseling
- Where
- 2 sites in India, United Kingdom
- Volunteers
- 150 people
- Sponsor
- University of Westminster
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
This phase IV trial studies how well human papillomavirus (HPV) vaccine therapy works in interrupting progression in patients with high-grade vulvar or anal lesions.
- Trial name
- NCT03051516
- Testing
- Laboratory Biomarker Analysis, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- 2 sites in United States
- Volunteers
- 188 people
- Sponsor
- Fred Hutchinson Cancer Center
SCLC, Limited Stage, Radiation Exposure
Omitting CTV for Primary Tumor in LS-SCLC
This randomized controlled non-inferior trial prospectively enrolled patients with limited-stage small cell lung cancer (LS-SCLC).
- Conditions
- SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect, Progression
- Trial name
- NCT07008716
- Testing
- Radiation Therapy, Etoposide + carboplatin; Etoposide + cisplatin, Creating CTV for primary tumor
- Where
- 2 sites in China
- Volunteers
- 852 people
- Sponsor
- Sun Yat-sen University
Neoplasms, Breast
Lapatinib and Bevacizumab for Metastatic Breast Cancer
This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.
- Trial name
- NCT00444535
- Testing
- lapatinib, bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib…
- Conditions
- Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma
- Trial name
- NCT07703436
- Testing
- Safusidenib
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Nuvation Bio Inc.
Breast Cancer
Genes That Affect Disease Progression in Women With Newly Diagnosed or Metastatic Breast Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and help doctors understand how patients respond to treatment.
- Trial name
- NCT00463034
- Testing
- microarray analysis, polymerase chain reaction, polymorphism analysis
- Where
- United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- University of Sheffield
Cervical Cancer
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
This trial is a multicenter, single-arm, phase 2 study of pembrolizumab in combination with olaparib in recurrent or metastatic cervical cancer patients who had disease progression during or after platinum-based chemotherapy.
- Trial name
- NCT04641728
- Testing
- Pembrolizumab, Olaparib
- Where
- Japan
- Volunteers
- 28 people
- Sponsor
- Saitama Medical University International Medical Center
Acute Myeloid Leukemia
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
This study includes patients with relapsed acute leukemia who have previously been treated with standard treatment that is still present and there is no curative treatment option available.
- Trial name
- NCT03374332
- Testing
- Gemtuzumab Ozogamicin (GO), Donor Leukocytes
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Breast Cancer
A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer
This 2 arm study compared the efficacy and safety of label dose of capecitabine (Xeloda®) to that of a lower dose of Xeloda® plus docetaxel (Taxotere®) in patients with locally advanced or metastatic breast cancer after failure…
- Trial name
- NCT00077857
- Testing
- capecitabine (Xeloda®), docetaxel (Taxotere®)
- Where
- 94 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 470 people
- Sponsor
- Hoffmann-La Roche
Epithelial Ovarian Cancer, High-grade Serous Ovarian Carcinoma
Chromosomal Instability in Ovarian Cancer
Chromosomal instability (CIN) refers to the ongoing genomic change, which involves the amplification or deletion of chromosome copy number or structure.
- Conditions
- Epithelial Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Chromosomal Instability, Somatic Copy Number Distortion
- Trial name
- NCT05310357
- Testing
- Testing for chromosomal instability (CIN)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Lei Li
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
This phase II trial is studying how well bortezomib followed by doxorubicin at the time of disease progression works in treating patients with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (cancer) of the…
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00077428
- Testing
- bortezomib, doxorubicin hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Allogeneic stem cell (allo SCT) transplantation for multiple myeloma is a potential curative treatment, but is associated with morbidity and treatment related mortality.
- Trial name
- AlloRelapseMM (NCT05675319)
- Testing
- Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD)
- Where
- 30 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Relapsed and Refractory Multiple Myeloma (RRMM)
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Primary Objective: 1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after…
- Trial name
- NCT05673967
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Early Gastric Cancer, Gastric Adenocarcinoma
Early Gastric Cancer in the Spanish EURECCA Registry
Early gastric cancer (EGC) is increasingly diagnosed in Western countries; however, important differences remain with Eastern populations regarding staging accuracy, treatment strategies, and the risk of lymph node metastasis.
- Trial name
- NCT07781319
- Volunteers
- 600 people
- Sponsor
- Corporacion Parc Tauli
Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) or has increased in size after…
- Trial name
- NCT02710253
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 214 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.